Scarica l'app Stockscreener
9.38
5.16%
-0.51
Dopo l'orario di chiusura:
9.32
-0.06
-0.64%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$9.89
Aprire:
$9.82
Volume 24 ore:
4.56M
Relative Volume:
1.17
Capitalizzazione di mercato:
$595.64M
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-4.0783
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
+0.00%
1M Prestazione:
-82.39%
6M Prestazione:
-74.63%
1 anno Prestazione:
-80.90%
Intervallo 1D:
$9.25
$10.13
Intervallo di 1 settimana:
$9.25
$10.95
Portata 52W:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Confronta MLTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
9.38 | 643.90M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-09-30 | Downgrade | Citigroup | Buy → Neutral |
| 2025-09-30 | Downgrade | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Downgrade | Stifel | Buy → Hold |
| 2025-07-28 | Iniziato | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-05 | Ripresa | Wedbush | Outperform |
| 2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-11-02 | Iniziato | Stifel | Buy |
| 2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Iniziato | Needham | Buy |
| 2023-06-15 | Iniziato | Barclays | Equal Weight |
| 2023-05-01 | Iniziato | Guggenheim | Buy |
| 2023-03-22 | Iniziato | Wedbush | Outperform |
| 2023-03-09 | Iniziato | BTIG Research | Buy |
| 2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Iniziato | Bryan Garnier | Buy |
| 2022-11-11 | Iniziato | Jefferies | Buy |
| 2022-08-25 | Iniziato | SVB Leerink | Outperform |
| 2022-07-21 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
Berger Montague PC Investigating Claims on Behalf of MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors After Class Action Filing - MarketScreener
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) INVESTOR ALERT - GlobeNewswire
Rosen Law Firm Urges MoonLake Immunotherapeutics (NASDAQ: MLTX) Stockholders with Large Losses to Co - PharmiWeb.com
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages MoonLake - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of MoonLake Immunotherapeutics, Inc. Investors - GlobeNewswire
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - FinancialContent
Rosen Law Firm Urges MoonLake Immunotherapeutics (NASDAQ: MLTX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - The Joplin Globe
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Chief Financial Officer of MoonLake Immunotherapeutics Matthias Bodenstedt Buys 1.8% More Shares - simplywall.st
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - WV News
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Stockholder Alert: Robbins LLP Informs MoonLake Immunotherapeutics Stockholders that a Class Action Lawsuit was Filed Against the Company - PR Newswire
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire Inc.
MoonLake Immunotherapeutics (MLTX) Investors with - GlobeNewswire
MoonLake Immunotherapeutics Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – MLTX - FinancialContent
MoonLake Immunotherapeutics (MLTX) Investors with Substantial Losses Have Opportunity to Lead the MoonLake Class Action Lawsuit -- RGRD LLP - MarketScreener
MOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
SHAREHOLDER ALERT: MoonLake Immunotherapeutics Sued For Securities Fraud by Block & Leviton LLP; December 15 Deadline To Seek To Serve As Lead Plaintiff - GlobeNewswire
Can MoonLake Immunotherapeutics stock beat analyst upgradesAnalyst Downgrade & High Conviction Trade Alerts - newser.com
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman - PR Newswire
How to interpret RSI for MoonLake Immunotherapeutics stockJuly 2025 Decliners & Capital Efficient Trade Techniques - newser.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of “Hold” by Brokerages - Defense World
MLTX Investor News: If You Have Suffered Losses in MoonLake - GlobeNewswire
Levi & Korsinsky Investigates Possible Securities Fraud by MoonLake Immunotherapeutics (MLTX) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake ImmunotherapeuticsMLTX - PR Newswire
Using AI based signals to follow MoonLake ImmunotherapeuticsEarnings Miss & AI Forecast Swing Trade Picks - newser.com
ATTENTION MoonLake Immunotherapeutics (MLTX) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action InvestigationMLTX - Eastern Progress
Shareholders Alert: Investigation Into MoonLake Immunotherapeutics (MLTX)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics - GlobeNewswire
Why Are MoonLake's (MLTX) Trial Setbacks Raising New Questions About Management Credibility and Regulatory Risks? - simplywall.st
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on - GuruFocus
2025-10-10 | MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics | NDAQ:MLTX | Press Release - Stockhouse
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpShould You Buy? - MarketBeat
MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money - GlobeNewswire
CFO Makes Bold Move with Major Stock Purchase in MoonLake Immunotherapeutics - TipRanks
MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & - GlobeNewswire
Oklahoma City NewsThe Oklahoman - FinancialContent
Insider Stock Purchases: October 09, 2025 - Quiver Quantitative
MoonLake Immunotherapeutics Stock (MLTX) Opinions on Phase 3 Trial Setback - Quiver Quantitative
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages MoonLake Immunotherapeutics (MLTX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Insider Buying: Matthias Bodenstedt Acquires Shares of MoonLake Immunotherapeutics - GuruFocus
Bodenstedt, MoonLake CFO, buys $98k in MLTX stock - Investing.com
BFA Law is Investigating MoonLake Immunotherapeutics (MLTX) for Securities Fraud and Urges Shareholders to Contact the Firm - Newsfile
Measuring MoonLake Immunotherapeutics’s beta against major indicesFed Meeting & Daily Growth Stock Tips - newser.com
Can Legal Pressures Reshape Confidence in MoonLake Immunotherapeutics’ (MLTX) R&D Pipeline? - Yahoo Finance
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny - GlobeNewswire
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moonlake Immunotherapeutics Azioni (MLTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Chen Bihua | Former 10% Owner |
Sep 29 '25 |
Sale |
7.21 |
6,494,151 |
46,827,628 |
2,000,000 |
| Chen Bihua | Former 10% Owner |
Sep 30 '25 |
Sale |
6.96 |
5,827 |
40,556 |
1,994,173 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Option Exercise |
0.00 |
23,500 |
0 |
23,500 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):